Publications by authors named "N K Leidy"

A COPD Foundation working group sought to identify measures of exercise endurance, a meaningful aspect of physical functioning in everyday life among patients with chronic obstructive pulmonary disease (COPD) that is not fully accepted in regulatory decision making, hampering drug development. To demonstrate, as we previously asserted (Casaburi 2022;9:252), that constant work rate cycling endurance time is an appropriate exercise endurance measure in patients with COPD. To validate this assertion, we assembled an integrated database of endurance time responses, including 8 bronchodilator (2,166 subjects) and 15 exercise training (3,488 subjects) studies (Casaburi 2022;9:520).

View Article and Find Full Text PDF

Introduction: Patient perception of the burden of chronic bronchitis symptoms in chronic obstructive pulmonary disease (COPD) can be assessed using patient-reported outcome measures (PROMs). The Cough and Sputum Assessment Questionnaire (CASA-Q) was developed and tested for this purpose. This study reviewed the performance of the CASA-Q in published online studies and tested a novel approach to complement traditional methods of qualitative content validation.

View Article and Find Full Text PDF

Accurately interpreting scores on patient-reported outcome (PRO) measures is essential to understanding and communicating treatment benefit. Over the years, terminology and methods for developing recommendations for PRO score interpretation in clinical trials have evolved, leading to some confusion in the field. The phrase "minimal clinically important difference (MCID)" has been simplified to "minimal important difference (MID)" and use of responder thresholds to interpret statistically significant treatment effects has increased.

View Article and Find Full Text PDF
Article Synopsis
  • * The study analyzed symptom variability using within-subject standard deviation (WS-SD) based on daily questionnaires from participants in the SPIROMICS Exacerbations sub-study, finding that those with higher variability scored worse on quality of life assessments.
  • * WS-SD is a reliable measure of symptom variability in COPD and indicates that greater variability is linked to poorer health-related quality of life, suggesting it needs further validation for clinical relevance.
View Article and Find Full Text PDF